Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...He said its products complied with the EU’s “extremely strict” production standards and that its factories were comparable “to the Pfizers of the world”....
...Soriot’s new pay deal comes after the company hit a $45bn sales target in 2023 that the chief executive had set in 2014 when the company fended off a takeover bid from US rival Pfizer....
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...GSK has sued Pfizer and BioNTech, alleging that their pharmaceutical rivals’ Covid-19 vaccine infringed “revolutionary” mRNA patents the British company filed in 2010....
...In February, the UK pharmaceuticals company hit a long-term sales target that once seemed out of reach....
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Shah Capital now owns 6.7 per cent of Novavax, having first bought into the company in the last quarter of 2022....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...He now hopes to bring a case to trial alleging that the product — sold by GSK, Sanofi, Pfizer and Boehringer Ingelheim over many years, caused his disease....
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...A Humira biosimilar from Teva Pharmaceuticals working with Alvotech earlier this year became the first drug that the US Food and Drug Administration granted interchangeable status, which lets pharmacists...
...Uptake of GSK’s Arexvy jab has far outstripped Pfizer’s Abrysvo so far, raising hopes that the rollout could mark a shift in fortunes for the UK company....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...WuXi AppTec is a major supplier of essential ingredients to many of the largest global pharmaceutical companies and conducts drug development for them....
...Any rumours that the company is at risk of defaulting are “flatly untrue”, he said....
...Shockwave’s technology has treated approximately 400,000 patients globally, the company said....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...Since it was spun off from pharmaceutical giant GSK in 2022, the London-listed company has taken steps to streamline its business with a restructuring programme and job cuts, together with the disposal of...
International Edition